Quick Answer
Merck & Co., Inc. reported Total Revenue of $65.01 billion for fiscal year 2025.
Merck & Co., Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $65.01B +1.3% |
$64.17B +6.7% |
$60.12B +1.4% |
$59.28B +21.7% |
$48.70B +17.3% |
$41.52B +6.1% |
| Net Income | $18.25B +6.6% |
$17.12B +4589.6% |
$365.00M -97.5% |
$14.52B +11.3% |
$13.05B +84.6% |
$7.07B -28.2% |
| Diluted EPS | $7.28 +8.0% |
$6.74 +4714.3% |
$0.14 -97.5% |
$5.71 +11.1% |
$5.14 +84.9% |
$2.78 -27.0% |
| Total Assets | $136.87B +16.9% |
$117.11B +9.8% |
$106.67B -2.3% |
$109.16B +3.3% |
$105.69B +15.4% |
$91.59B +8.5% |
| Cash and Equivalents | $14.56B +10.0% |
$13.24B +93.6% |
$6.84B -46.1% |
$12.69B +56.8% |
$8.10B +0.6% |
$8.05B -16.8% |
| Long-Term Debt | $46.75B +35.7% |
$34.46B +2.3% |
$33.68B +17.2% |
$28.75B -6.3% |
$30.69B +21.0% |
$25.36B +11.5% |
| Stockholders Equity | $52.61B +13.6% |
$46.31B +23.2% |
$37.58B -18.3% |
$45.99B +20.4% |
$38.18B +50.8% |
$25.32B -2.3% |
| R&D Expense | $15.79B -12.0% |
$17.94B -41.2% |
$30.53B +125.4% |
$13.55B +10.6% |
$12.24B -8.6% |
$13.40B +37.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $17.28B | +3.7% | +9.3% |
| Net Income | September 30, 2025 | $5.79B | +83.2% | +30.7% |
| Diluted EPS | September 30, 2025 | $2.32 | +87.1% | +31.8% |
| Total Assets | September 30, 2025 | $129.55B | +10.2% | +10.2% |
| Cash and Equivalents | September 30, 2025 | $18.17B | +24.5% | +126.9% |
| Long-Term Debt | September 30, 2025 | $39.97B | +14.3% | +17.7% |
| Stockholders Equity | September 30, 2025 | $51.85B | +16.5% | +5.8% |
| R&D Expense | September 30, 2025 | $4.23B | -27.8% | +4.6% |
- Merck & Co., Inc. reported Total Revenue of $65.01 billion for fiscal year 2025.
- Merck & Co., Inc. showed an increase of +1.3% in Total Revenue compared to the prior fiscal year.
- Merck & Co., Inc. reported Net Income of $18.25 billion for fiscal year 2025.
- Merck & Co., Inc. showed an increase of +6.6% in Net Income compared to the prior fiscal year.
- Merck & Co., Inc. reported Diluted EPS of $7.28 per share for fiscal year 2025.
- Merck & Co., Inc. showed an increase of +8.0% in Diluted EPS compared to the prior fiscal year.
- Merck & Co., Inc. reported Total Assets of $136.87 billion for fiscal year 2025.
- Merck & Co., Inc. showed an increase of +16.9% in Total Assets compared to the prior fiscal year.
- Merck & Co., Inc. reported Cash and Equivalents of $14.56 billion for fiscal year 2025.
- Merck & Co., Inc. showed an increase of +10.0% in Cash and Equivalents compared to the prior fiscal year.
- Merck & Co., Inc. reported Long-Term Debt of $46.75 billion for fiscal year 2025.
- Merck & Co., Inc. showed an increase of +35.7% in Long-Term Debt compared to the prior fiscal year.
- Merck & Co., Inc. reported Stockholders Equity of $52.61 billion for fiscal year 2025.
- Merck & Co., Inc. showed an increase of +13.6% in Stockholders Equity compared to the prior fiscal year.
- Merck & Co., Inc. reported R&D Expense of $15.79 billion for fiscal year 2025.
- Merck & Co., Inc. showed a decrease of -12.0% in R&D Expense compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: